Skip to main content
Top

memo - Magazine of European Medical Oncology

Issue 1/2023

Content (20 Articles)

Hodgkin Lymphoma short review

Hodgkin lymphoma—how much therapy do we need?

Barbara Lehner, Michael Panny

Open Access Lymphoma short review

Cutaneous lymphomas—fast facts about an orphan disease—a short review

Stefanie Porkert, Julia Valencak

Open Access Lymphoma short review

News on Peripheral T-cell lymphoma

Alexander Pichler

Rectal Cancer short review

Total neoadjuvant therapy in rectal cancer

Gudrun Piringer, Alexander De Vries

Open Access Metastasis short review

Surgical management of liver metastasis from colorectal cancer

Madita-Magdalena Tschoegl, Thomas Gruenberger

Best of hematology—2021

Katharina Theresa Prochazka

Open Access Breast Cancer short review

Biomarkers and translational research approaches in breast cancer—an update

Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch

Open Access Cabozantinib short review

Essential news for clinical practice—thyroid cancer

Barbara Kiesewetter, Ladislaia Wolff, Markus Raderer

Open Access Prostate Cancer short review

Theranostics in prostate cancer

Rainer W. Lipp

Open Access Lymphoma position paper

Barriers to patient access of CAR T cell therapies in Austria

Georg Hopfinger, Bernhard Rupp, Richard Greil

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine